Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China.
Chunwei XuZhanhong ChenYuanli XiaYanxia ShiPeifen FuYi-Ding ChenXian WangLili ZhangHengyu LiWenyan ChenJianfei FuLiming HuangJingde ShuOuchen WangWeizhu WuBojian XieTing WangWeiping ZhangShurong ShenQun LiTing LuoBin ZhangYanru XieHongxia WangQian WangWen-Xian WangZiming LiZhengbo SongWenfeng FangWen-Zhao ZhongYongchang ZhangPing ZhanHongbing LiuTangfeng LvLi-Yun MiaoLingfeng MinFeng WangRui MengYoucai ZhuLin WangBing WanDong WangYue HaoJianya ZhouLong HuangZhang ZhangDonglai LvMeiyu FangYuanzhi LuLu SiYong SongXiaojia WangPublished in: Cancer (2024)
Antibody-drug conjugates (ADCs) have demonstrated effectiveness in treating various cancers, particularly exhibiting specificity in targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Recent advancements in phase 3 clinical trials have broadened current understanding of ADCs, especially trastuzumab deruxtecan, in treating other HER2-expressing malignancies. This expansion of knowledge has led to the US Food and Drug Administration's approval of trastuzumab deruxtecan for HER2-positive and HER2-low breast cancer, HER2-positive gastric cancer, and HER2-mutant nonsmall cell lung cancer. Concurrent with the increasing use of ADCs in oncology, there is growing concern among health care professionals regarding the rise in the incidence of interstitial lung disease or pneumonitis (ILD/p), which is associated with anti-HER2 ADC therapy. Studies on anti-HER2 ADCs have reported varying ILD/p mortality rates. Consequently, it is crucial to establish guidelines for the diagnosis and management of ILD/p in patients receiving anti-HER2 ADC therapy. To this end, a panel of Chinese experts was convened to formulate a strategic approach for the identification and management of ILD/p in patients treated with anti-HER2 ADC therapy. This report presents the expert panel's opinions and recommendations, which are intended to guide the management of ILD/p induced by anti-HER2 ADC therapy in clinical practice.
Keyphrases
- interstitial lung disease
- epidermal growth factor receptor
- systemic sclerosis
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- tyrosine kinase
- clinical practice
- healthcare
- advanced non small cell lung cancer
- clinical trial
- endothelial cells
- positive breast cancer
- randomized controlled trial
- drug administration
- diffusion weighted
- type diabetes
- cell therapy
- risk factors
- oxidative stress
- cardiovascular events
- single cell
- drug delivery
- young adults
- squamous cell carcinoma
- radiation therapy
- contrast enhanced
- social media
- case control
- stress induced
- pluripotent stem cells
- structural basis